Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical Pharmacokinetics
Published in: Clinical Pharmacokinetics 4/2000

01-04-2000 | Original Research Article

A Concept for Pharmacokinetic-Pharmacodynamic Dosage Adjustment in Renal Impairment

The Case of Aminoglycosides

Authors: David Czock, Michael Giehl, Prof. Dr Frieder Keller

Published in: Clinical Pharmacokinetics | Issue 4/2000

Login to get access

Abstract

Background: For patients with impaired renal function, dosage adjustment is necessary for many drugs. Adjustment with respect only to pharmacokinetic parameters may be insufficient.
Objective: To apply the theory of pharmacokinetics and pharmacodynamics to derive a mathematical model that links the concentration-time course and the clinical response by means of the pharmacokinetic-pharmacodynamic parameter ‘area under the effect-time curve’ (AUETC), and to use this analysis and clinical data for aminoglycosides to calculate dosage adjustments in renal impairment.
Methods: Model parameters were estimated for the antimicrobial and nephrotoxic effects of aminoglycosides on the basis of data from the literature. Effect parameters were calculated for various degrees of impaired renal function.
Results: Use of the model parameters gave a high correlation between the predicted and the observed (literature) values for antimicrobial efficacy and nephrotoxicity. When calculating dosage adjustments in renal impairment, it was possible to hold only one effect (antimicrobial or nephrotoxic) constant by dosage adjustment, whereas the other changed unfavourably. This was explained by differences between the pharmacodynamic parameters for each effect. For high antimicrobial efficacy, a target peak concentration of 9 mg/L (for gentamicin) should be obtained every 48 hours in advanced renal impairment. For low nephrotoxicity, the peak concentration should not exceed 3 mg/L.
Conclusions: The parameter AUETC could be a useful pharmacokinetic-pharmacodynamic surrogate marker for dosage adjustment in renal impairment. Using the AUETC method, the beneficial effect can be balanced against the adverse effect.
Literature
1.
Kunin CM. A guide to use of antibiotics in patients with renal disease. Ann Intern Med 1967; 67: 151–8PubMed
2.
Barth RH, DeVincenzo N. Use of vancomycin in high-flux hemodialysis: experience with 130 courses of therapy. Kidney Int 1996; 50: 929–36PubMedCrossRef
3.
Keller F, Borner K, Schwarz A, et al. Therapeutic aminoglycoside monitoring in renal failure patients. Ther Drug Monit 1987; 9: 148–53PubMedCrossRef
4.
Dettli L. Drug dosage in patients with renal disease. Clin Pharmacol Ther 1974; 16: 274–80PubMed
5.
Holford NHG. The target concentration approach to clinical drug development. Clin Pharmacokinet 1995; 29: 287–91PubMedCrossRef
6.
Perna A, Gotti E, De Bernardis E, et al. A logistic-regression model provides novel guidelines to maximize the anti-acute rejection properties of cyclosporine with a minimum of toxicity. J Am Soc Nephrol 1996; 7: 786–91PubMed
7.
Zhi J, Nightingale CH, Quintiliani R. Microbial pharmacodynamics of piperacillin in neutropenic mice of systematic infection due to Pseudomonas aeruginosa. J Pharmacokinet Biopharm 1988; 16: 355–75PubMed
8.
Nolting A, Dalla-Costa T, Rand KH, et al. Pharmacokineticpharmacodynamic modeling of the antibiotic effect of piperacillin in vitro. Pharm Res 1996; 13: 91–6PubMedCrossRef
9.
Mouton JW, Vinks AATMM, Punt NC. Pharmacokineticpharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion. Antimicrob Agents Chemother 1997; 41: 733–8PubMed
10.
Wagner JG. Kinetics of pharmacological response. I. Proposed relationship between response and drug concentration in the intact animal and man. J Theoret Biol 1968; 20: 173–201CrossRef
11.
12.
Hochhaus G, Derendorf H. Dose optimization based on pharmacokinetic-pharmacodynamic modeling. In: Derendorf H, Hochhaus G, editors. Handbook of PK/PD correlation. Boca Raton: CRC Press, 1995: 79–120
13.
Wiedemann B, Jansen A. Antibacterial activity of cefpodoxime proxetil in a pharmacokinetic in-vitro model. J Antimicrob Chemother 1990; 26: 71–9PubMedCrossRef
14.
Firsov AA, Shevchenko AA, Vostrov SN, et al. Inter- and intraquinolone predictors of antimicrobial effect in an in vitro dynamic model: new insight into a widely used concept. Antimicrob Agents Chemother 1998; 42: 659–65PubMed
15.
Hill AV. The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves. J Physiol (Proc Physiol Soc) 1910; 40: iv–vii
16.
Dayneka NL, Garg V, Jusko WJ. Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 1993; 21: 457–78PubMed
17.
Krzyzanski W, Jusko WJ. Integrated functions for four basic models of indirect pharmacodynamic response. J Pharm Sci 1998; 87: 67–72PubMedCrossRef
18.
Czock D, Giehl M. Aminoglycoside pharmacokinetics and — dynamics: a nonlinear approach. Int J Clin Pharmacol Ther 1995; 33: 537–9PubMed
19.
Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155: 93–9PubMedCrossRef
20.
Prins JM, Buller HR, Kuijper EJ, et al. Once versus thrice-daily gentamicin in patients with serious infections. Lancet 1993; 341: 335–9PubMedCrossRef
21.
Matzke GR, Jameson JJ, Halstenson CE. Gentamicin disposition in young and elderly patients with various degrees of renal function. J Clin Pharmacol 1987; 27: 216–20PubMed
22.
Halstenson CE, Wong MO, Herman CS, et al. Effect of concomitant administration of piperacillin on the dispositions of isepamicin and gentamicin in patients with end-stage renal disease. Antimicrob Agents Chemother 1992; 36: 1832–6PubMedCrossRef
23.
Weiner DL. NONLIN84/PCNONLIN: software for the statistical analysis of nonlinear models. Methods Find Exp Clin Pharmacol 1986; 8: 625–8PubMed
24.
Gibaldi M, Levy G. Dose-dependent decline of pharmacologic effects of drugs with linear pharmacokinetic characteristics. J Pharm Sci 1972; 61: 567–9PubMedCrossRef
25.
Karlsson MO, Molnar V, Bergh J, et al. A general model for time-dissociated pharmacokinetic-pharmacodynamic relationships exemplified by paclitaxel myelosuppression. Clin Pharmacol Ther 1998; 63: 11–25PubMedCrossRef
26.
Bouvier d’Yvoire MJY, Maire PH. Dosage regimens of antibacterials. Implications of a pharmacokinetic/pharmacodynamic model. Clin Drug Invest 1996; 11: 229–39CrossRef
27.
Yano Y, Oguma T, Nagata H, et al. Application of logistic growth model to pharmacodynamic analysis of in vitro bactericidal kinetics. J Pharm Sci 1998; 87: 1177–83PubMedCrossRef
28.
Mouton JW, Van Ogtrop ML, Andes D, et al. Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo. Antimicrob Agents Chemother 1999; 43: 2473–8PubMed
29.
Hyatt JM, McKinnon PS, Zimmer GS, et al. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin Pharmacokinet 1995; 28: 143–60PubMedCrossRef
30.
Bastone EB, Li Shu C, Ioannides-Demos LL, et al. Kill kinetics and regrowth patterns of Escherichia coli exposed to gentamicin concentration-time profiles simulating in vivo bolus and infusion dosing. Antimicrob Agents Chemother 1993; 37: 914–7PubMedCrossRef
31.
Rayner CR, Ioannides-Demos LL, Brien JE, et al. Initial concentration-time profile of gentamicin determines efficacy against Enterobacter cloacae ATCC 13047. Antimicrob Agents Chemother 1998; 42: 1370–4PubMed
32.
Hatala R, Dinh T, Cook DJ. Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis. Ann Intern Med 1996; 124: 717–25PubMed
33.
Giuliano RA, Verpooten GA, Verbist L, et al. In vivo uptake kinetics of aminoglycosides in the kidney cortex of rats. J Pharmacol Exp Ther 1986; 236: 470–5PubMed
34.
Takano M, Ohishi Y, Okuda M, et al. Transport of gentamicin and fluid-phase endocytosis markers in the LLC-PK1 kidney epithelial cell line. J Pharmacol Exp Ther 1994; 268: 669–74PubMed
35.
Wood CA, Norton DR, Kohlhepp SJ, et al. The influence of tobramycin dosage regimens on nephrotoxicity, ototoxicity, and antibacterial efficacy in a rat model of subcutaneous abscess. J Infect Dis 1988; 158: 13–22PubMedCrossRef
36.
Bertino JS, Booker LA, Franck PA, et al. Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring. J Infect Dis 1993; 167: 173–9PubMedCrossRef
37.
Bennett WM, Plamp CE, Gilbert DN, et al. The influence of dosage regimen on experimental gentamicin nephrotoxicity: dissociation of peak serum levels from renal failure. J Infect Dis 1979; 140: 576–80PubMedCrossRef
38.
Giuliano RA, Verpooten GA, De Broe ME. The effect of dosing strategy on kidney cortical accumulation of aminoglycosides in rats. Am J Kidney Dis 1986; 5: 297–303
39.
Verpooten GA, Giuliano RA, Verbist L, et al. Once-daily dosing decreases renal accumulation of gentamicin and netilmicin. Clin Pharmacol Ther 1989; 45: 22–7PubMedCrossRef
40.
Nicolau DP, Freeman CD, Belliveau PP, et al. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother 1995; 39: 650–5PubMedCrossRef
41.
Pattyn VM, Verpooten GA, Giuliano RA, et al. Effect of hyperfiltration, proteinuria and diabetes mellitus on the uptake kinetics of gentamicin in the kidney cortex of rats. J Pharmacol Exp Ther 1988; 244: 694–8PubMed
42.
Kirkpatrick CMJ, Duffull SB, Begg EJ. Pharmacokinetics of gentamicin in 957 patients with varying renal function dosed once daily. Br J Clin Pharmacol 1999; 47: 637–43PubMedCrossRef
43.
Schentag JJ, Jusko WJ, Vance JW, et al. Gentamicin disposition and tissue accumulation on multiple dosing. J Pharmacokinet Biopharm 1977; 5: 559–77PubMed
44.
Begg EJ, Barclay ML, Duffull SB. A suggested approach to once-daily aminoglycoside dosing. Br J Clin Pharmacol 1995; 39: 605–9PubMedCrossRef
Metadata
Title
A Concept for Pharmacokinetic-Pharmacodynamic Dosage Adjustment in Renal Impairment
The Case of Aminoglycosides
Authors
David Czock
Michael Giehl
Prof. Dr Frieder Keller
Publication date
01-04-2000
Publisher
Springer International Publishing
Published in
Clinical Pharmacokinetics / Issue 4/2000
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI
https://doi.org/10.2165/00003088-200038040-00005

Other articles of this Issue 4/2000

Clinical Pharmacokinetics 4/2000 Go to the issue

Review Article

Metabolism and Pharmacokinetics of Oxazaphosphorines

Review Article

Pharmacokinetic Drug Interactions Between Oral Contraceptives and Second-Generation Anticonvulsants

Review Article

Adaptive Control Methods for the Dose Individualisation of Anticancer Agents

Review Article

Magnesium Sulfate in Eclampsia and Pre-Eclampsia